Last checked at 
Creo Medical Group PLC - medical device company headquartered in Chepstow, Wales - Notes the first in-human use of its "life-changing" MicroBlate Fine device, treating a patient with an unresectable pancreatic neuroendocrine tumour.
Device is used to successfully ablate pancreatic tumour tissue under endoscopic ultrasound guidance and can add months to patients life expectancy and well-being, Creo says.
The procedure was performed at Instituto Ecuatoriano de Enferemdades Digestives in Ecuador with a successful resulting outcome. Creo says the patient suffered with a condition that could not be treated surgically using traditional methods and instead required a less invasive treatment. Subsequent scans of the patient's pancreas continue to "confirm the treatment's durability".
Creo Chief Executive Craig Gulliford comments: "We are delighted to report such a positive update. The device was successfully used for the first in-human minimally invasive endoscopic ultrasound guided treatment in a patient with an unresectable pancreatic neuroendocrine tumour in December 2020.
"The outcome of the procedure was a success, with subsequent follow up scans not only showing no return of the tumour, but also an absence of any obvious scar tissue."
Current stock price: 220.00 pence; up 6.8% on Wednesday
Year-to-date change: up 13%
By Will Paige; willpaige@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
